




Humber Local Pharmaceutical Committee

# Annual Report

## April 2023 to March 2024



Paul J. McGorry BSc (Hons), MRPharmS, FRSPH, MAPCPharm  
Chief Executive Officer

Community Pharmacy Humber (Humber LPC)

PO Box 656, HULL, HU9 9RL

T: 01482 335824

[p.mcgorry@nhs.net](mailto:p.mcgorry@nhs.net) [www.communitypharmacyhumber.co.uk](http://www.communitypharmacyhumber.co.uk)

## Chairs Annual report for 23/24



As the Chair of Community Pharmacy Humber, it is my pleasure to present our annual report for the year 2023-24. This report encapsulates our collective efforts, achievements, and ongoing initiatives aimed at enhancing community pharmacy services across the Humber region. The past year has been marked by significant developments and milestones that reflect our unwavering commitment to the health and well-being of our community.

### Key Achievements:

#### 1. Establishment of the New Committee:

**Formation in July 2023:** A significant milestone this year was the establishment of our new committee in July 2023. This revitalised team has brought fresh perspectives and renewed energy to our strategic planning and execution.

**Strategy and vision:** The new committee agreed on a vision and strategy for the next three years, this will underpin the work plan delivered by the team.

#### 2. Enhanced Service Delivery:

**Innovative and Advanced Services:** Introduction of new advanced services, such as Pharmacy First (PF), along with the recommissioning of locally enhanced services, such as the Walk-in-consultation services (WiCS)

#### 3. Collaborative Initiatives:

**Partnerships:** Strengthened partnerships with Community Pharmacy North Yorkshire, the local medical committee, general practice teams, Places, local authorities and the Humber and North Yorkshire Integrated Care Board (ICB) have facilitated the introduction of new and a review of existing pharmacy services.

**Patient and public involvement:** Healthwatch representatives regularly attend and participate in committee meetings, this has facilitated the understanding of how community pharmacies operate and supported them with responding to queries from the public regarding pharmacy services.

### **Contractor engagement:**

Securing the engagement and dialogue with our community pharmacy teams remains a top priority. We have refreshed our communication methods, including the weekly digest, newsletter and social media accounts. Over the past year, we conducted several sessions and workshops focusing on areas such as:

**PF Clinical Skills Enhancement:** face-to-face workshops, supported by a local GP and City Healthcare Partnership CIC, aimed at improving clinical assessment skills, enabling pharmacists to deliver the PF advanced service competently and with confidence, which commenced in January 2024.

**Discharge Medicine Service & Smoking Cessation Service:** online events designed to enhance community and hospital pharmacy team interaction and service delivery.

**Drug Tariff tips and Pharmacy workflow:** face-to-face workshop supported by our regional Community Pharmacy England representative, available for all community pharmacy team members.

### **Community engagement:**

We have maintained communications with local councillors and members of parliament regarding community pharmacy issues. We have also engaged with local media platforms to highlight the challenges community pharmacy teams currently face and the services they can offer to their local communities.

### **Future Outlook:**

Looking ahead, we are committed to building on our achievements and addressing the evolving healthcare needs of our community. Our strategic priorities for the coming year include:

**Engagement and collaboration with contractors and stakeholders:** establish and nurture partnerships and organise regular forums, workshops and networking events to foster dialogue and collaboration, working with our colleagues at Community Pharmacy North Yorkshire.

**Strengthening Advocacy:** Advocating for the vital role of community pharmacies across the integrated care system, ensuring your contributions are recognised and supported.

**Contractor development and support:** engage with work to improve issues with workforce development in our geography aligned with the needs of contractors and any amendments to the community pharmacy contract.

### **Acknowledgements:**

I would like to extend my heartfelt gratitude to our dedicated pharmacy teams, whose hard work and professionalism underpin our success. I also thank our staff and committee members, stakeholders, and the community for their unwavering support and collaboration.

In conclusion, 2023-24 has been a year of significant progress and impactful service delivery for Community Pharmacy Humber. With the establishment of our new committee and the introduction of advanced services like Pharmacy First, we are well-positioned to continue our mission of providing exemplary pharmacy services to our community. We look forward to another year of growth and service.

***Joanne Lane, Chair, Community Pharmacy Humber***

## Chief Executive Officer's Report

I described 2022/23 by one word, 'Change'. That continued into 23/24, it still does even now, but perhaps the word for 23/24 was 'Survival'. This isn't just the negative connotations, of which we all know there are many, but the positive, surviving against the odds, 'what doesn't kill you makes you stronger' sort of thing. You are still here, not everyone is, but you are. In spite of the hurdles, strife, change and setbacks the pharmacy business still went on:



- The Wright review that begat RSG, which became TAPR, is now over as far as CPE is concerned and we work more closely with NYorks LPC within our ICS.
- Our lengthy support for DMS & SCS finally had both fully launched in the year. DMS delivery has progressed nicely over the year from only 233 interventions in Q1 to 481 in Q4. SCS is in its very early days.
- We have solidified our engagement with PCN Clinical directors and the 'Places' over the year and focused on developing our links with the now fully 'in charge' ICS and community pharmacies voice is being heard. Our closer working with the LMC continues to be beneficial.
- Most current services have been secured and fees enhanced as well as others brought in, such as WiCS2 resurrected at extremely short notice.
- The massive upheaval in contract closures and sales has been very time consuming.
- We have supported the OCMS pilot as it became the nationally contracted Pharmacy Contraception Service and supported its uptake, we have also been supporting the development of the Independent prescribing pathfinder which should also turn into national services eventually.
- Firefighting on various issues included the old favourite ordering of repeat prescriptions, many more queries and outright complaints around supply due to shortages which have on occasion reached MP level, fewer about unplanned closures but still complaints, surgery/practice pharmacist queries/asks and 'concerns' around Pharmacy First and practically every aspect of community pharmacy, 111, and many more...
- We have continued to Support the PCN leads, their work and ongoing recruitment & development.
- We tried to relocate our office into Health House for much of the year but the changing, expanding, needs of the ICS meant this was ultimately futile. We have secured an alternate site.

**In other activities:** A lot of work was done to position the LPC to have your voices represented within the developing future NHS: -

**Pharmacy Funding:** The funding stasis has become a crisis with the increased costs, especially with what was, and is, going on in the world, continuing to bite and push profitability into survivability for many. There had been hopes to see the 24/25 contract ready in time for Apr 1<sup>st</sup>, but this was not to be and so uncertainty and underfunding continue alongside the asks to do more.

**Flu Vaccination Service:** Another good year for Flu in community pharmacy, 73k+, alongside making a significant impact on the Covid vaccination effort. Pharmacy is increasingly being seen as the home of vaccinations thanks to your work.

**Market Entry & Exit [Formally Control of Entry]:** If 22/23s market was quiet then 23/24 was deafening. The implosion of Lloyds and lengthy process of selling nearly all of their contracts continued across the entire year. On the positive side all, barring the 2 Sainsburys sites, were sold meaning we have many new owners, and subsequently have increased our LPC independent ownership share to over 53%, which has carried through to our committee composition.

However the rationalisation of Boots estate did cost us 10 contracts.

There were, and remain, tentative signs of activity with new applications but they were centred around the closures and are struggling to make their cases.

23/24 also saw an easement granted to 100hr contractors to drop to 72hours, which practically all took, and when combined with many others trimming their opening hours, possibly to help viability, a significant number of opening hours were lost, with no signs of the trend stopping.

**Services:** A busy year for reviewing services and renegotiating with people new to the responsibility. This has been lengthy and involved, but eventually most services have been renewed and received fee increases, something Caroline will expand upon.

However, even with the uncertainty, it has been a good year for services. Comparing 22/23 with 23/24, and only those services that can be compared, we see a 6.3% growth in the total services value year on year with that services total reaching £913,088.19 up from £858,679.22 previously. The real number will be even higher if we knew how much was raised from the outsourced services within the patch that do not share data. Even in difficult times you have still been engaged and are utilising the services we have secured for you.

**To put the value of LPC secured services into context, for every £1 paid to the LPC in contractor levy a minimum of £3.22 comes back as services opportunity.** This doesn't include the outsourced services we don't see data for, or a share of the national advanced services that were negotiated by CPE but built locally by the LPC. That £3.22 will be much higher all things considered.

On the new services front, working with the new ICS, the Covid medication supply and delivery service, that went live in March 2023, has been continually renewed. We also successfully helped to transition the OCMS oral contraception pilot in Hull and North East Lincs to the new Pharmacy Contraception Service.

A large part of the services success last year was the walk-in consultation service (WiCS) that we proposed to NHSE and then built, heavily inspired by Cornwall's service. This ended in April 2023 and was, at very short notice, revived in January 2024 as WiCS2 to provide significant services income to contractors and help patients during NHS winter pressures season. Over its 10-week lifespan you delivered 4,981 interventions from 76 active sites. Maybe we will see WiCS3?

Of course the big new service this year was pharmacy first. Grouping & rebranding several existing services under one PF umbrella and rolling out the 7 clinical pathways with a plethora of PGDs that all had to be learned satisfactorily over Christmas, and the New Year, ready for a compromised IT launch. We provided support through comms and resources, along with the CPE webinars, but also delivered 2 face to face events around otitis media, delivered by a GP expert, that gave that hands on practice and tips from someone who does this every day. 71 of you attended those 2 hands on, very well received, events. PF Data is still scarce but from the 2 months in Q4 23/24 we can see a 13% increase month on month which hopefully continues.

**Workforce:** Workforce issues have been identified as a key issue for us in the Humber, as well as nationally. The LPC has tasked itself to get involved more deeply within the NHS structures to fight our case for support in this matter. We are now involved in various workforce initiatives and boards within the ICS, I am the ICS pharmacy workforce lead now with all of the involvement that title brings. In 23/24 a lot of work has been done to formalise community pharmacy's workforce position, and needs, within the primary care workforce, as well as the ICS workforce board, to add the necessary bureaucracy and plans that the NHS requires. Events have been held to support the creation of a formal ICS Pharmacy workforce plan which was developed in Q4 of 23/24 onwards with the aim of being finalised and signed off by the ICS in 24/25. The plan is broad ranging and does face into our workforce crisis now, as well as trying to maximise the upcoming opportunities from the new cohorts of foundation pharmacists, pre-regs, who qualify as IPs also from 2026. A lot more to come on this topic.

**Summary of LPC events / workshops offered April 2023 - March 2024:** The LPC directly facilitated PCN leads meetings with their contractors, launched SCS as well as the PF support/training in January/March. Throughout the year the LPC supported and signposted to various meetings by: CPPE, NHSE, PCNs, CPE. As well as our very well attended event on DMS training and GPhC peer review revalidation along with other events such as the maximising pharmacy income event in October 2023. More is planned in 24/25.

**The New Committee:** The old committee met for the final time in May23, coinciding with the retirement of our former chair. The new committee, with very little crossover, held its first meeting in July 2023. The committee is now a majority independent one with only one vacancy left to fill, a CCA place. The members have settled in well and are fully engaged with the work of the LPC.

We successfully recruited an employed chair.

Change is our norm and if 23/24 was indeed a year of *survival* what does that mean for 24/25? We can see big changes coming from summer 2026, but with so much change, even just what we already know of, it goes back to survival of the fittest to get there. But get there we shall...

**Local Pharmacy Services Income (commissioned by ICB) 2023-24**

	NHS Emergency supply (PURMS)	Minor Ailments Scheme	EL6B Medication records charts	Point of Dispensing Intervention Service (PODIS)	EL23 / Medication support service	Palliative Care stock holding	Out of Hours Palliative care service	Walk in Consultation Service (WiCS2)	Covid Medication Supply Service	Extended hours service	Total income per area
<b>East Riding</b>	£3,044.84	£35,124.17	£17,794.40	£3,719.24	£30.00	£1,671.88	N/A	£20,429.70	£2,257.66	N/A	<b>£84,071.89</b>
<b>Hull</b>	£6,248.16	£206,336.50	£22,346.60	£4,365.17	£3,728.00	£2,075.53	N/A	£42,126.60	£3,569.60	N/A	<b>£290,796.16</b>
<b>North East Lincolnshire</b>	N/A	£37,218.96	N/A	£849.41	N/A	£0	£25,929.48	£23,451.10	£2,059.70	N/A	<b>£89,508.65</b>
<b>North Lincolnshire</b>	N/A	£53,524.02	N/A	£7,307.81	N/A	£1,132.61	£19,907.95	£10,906.70	£1,779.00	£32,320.00	<b>£126,878.09</b>
<b>ICB commissioned Enhanced Pharmacy Services income 2023-24</b>											<b>£591,254.79</b>

## Local Pharmacy Services income – Public Health 2023-2024

Local Pharmacy Services – Public Health 2023-2024 (* Commissioner Controlled Data)									Advanced Services/ other pilot services/ essential services			
	NHS Health checks	Sexual health / Emergency Hormonal Contraception	Smoking Cessation NRT	Needle exchange	Supervised Consumption Methadone	Supervised Consumption Buprenorphine	C-Card Scheme	Total Income	CPCS/PF	NMS	OCMS pilot became PCS	DMS & SCS
									Flu & Vaccs			
<b>East Riding</b>	£377 Fees	£13,135.68	£103,782.07	£4,002.10	£63,236.34	£61,056.00	N/A	£245,212.19	CPCS averaged 4400+ per quarter through the year, +47% on 22/23, before becoming PF.  Flu had a good year at over 73k+ delivered with many Covid Vaccs also.	Grew from 14,387 in Q1 to 20,452 in Q4	Available In Hull & NE Lincs. 12 tier 1 sites in end Apr 2023. To delivering 446 Humber PCS consults by end of Q4	Grew from 233 DMS in Q1 to 481 in Q4.
<b>Hull</b>	N/A	£29,856.55	Unknown *	£27,693.12	Unknown	Unknown *	N/A	£57,549.67				
<b>North East Lincolnshire</b>	N/A	£18,525.53	N/A	Unknown *	Unknown *	Unknown *	£169.01	£18,694.54				
<b>North Lincolnshire</b>	N/A	N/A	N/A	Unknown *	Unknown *	Unknown *	N/A	£0				
<b>Public health commissioned services TOTAL INCOME (where known)</b>								<b>£321,833.40</b>				

**2023/24 Combined Total services income PH & ICB (where known)**

**£913,088.19**

For comparison purposes: 2022/23 Combined Total services income PH & CCG (comparable where known) = £858,679.22



## The Teams Year –

### **Caroline Hayward: Professional Development Pharmacist**

My year focused on retention and fee re-negotiation for locally commissioned Integrated Care Board (ICB) and public health services; design and implementation of new local services; PharmOutcomes platform redesigns and builds; Overseas workforce visit; Supporting national pharmacy services; Design and delivery of training events and production of Patient Group Directions to support local pharmacy and dental services.



Renegotiation of the fees and service continuation associated with ICB commissioned services was a lengthy process which included cost modelling and service impact evaluations. Uplifted fees were finally agreed for the majority of services. Sadly, the Point of Dispensing intervention service (PODIS) and Pharmacy Urgent Repeat Medicines service (PURMS) were not recommissioned for 2024-25. During 2024-2025 pharmacies will see revised service specifications and uplifted fees implemented for all of the remaining ICB commissioned services.

New service launches included implementation of a Walk in Consultation Service across Humber and North Yorkshire in January 2024 when additional funds were secured to support winter pressures. This service aligned with the national Pharmacy first minor illness service but allowed patients to self-refer.

Other services relaunched and updated during the year included:

- The Optical referral into Hypertension case finding service which relaunched with a new PharmOutcomes platform and referral guidelines for optical practices.
- The COPD review pilot service expanded to include pharmacy initiation of a COPD review and associated PharmOutcomes platforms builds. This pilot has now finished.
- Contracts were renegotiated for the Hull needle exchange service, resulting in an increase in service fees, the building and implementation of a new PharmOutcomes platform and new funding to support the introduction of an additional needle exchange pharmacy in Hull.
- The North Lincolnshire supervised consumption and needle exchange services were re-negotiated and increased fees secured.
- All East Riding council commissioned service fees were renegotiated and a significant increase to all service fees was achieved with implementation from 1<sup>st</sup> April 2024.

Review of the North East Lincolnshire ACT (Advice Contraception & Treatment service) started in 2023 and is almost complete with a new service offer and significant fee increase coming soon.

The ICB requested a review of the current local services PharmOutcomes (PO) arrangements with Humber LPC; extensive work was undertaken to model and review the current arrangements and to design a future PO model across the ICB to include the use of combined service platforms for all place areas within the ICB. PharmOutcomes Platforms are currently being redesigned and rebuilt in line with the vision and will be released and incorporated into services throughout 2024.

Additional PO work arose due to a change in the VAT legislation for medications provided under a PGD; from 1<sup>st</sup> May 2023 meds provided via PGD became VAT exempt, hence once commissioners had approved the change, funding rules within PO were updated in line with the new legislation.

May 2023 was an exciting month as I was invited by the ICB to visit Kerala in India to investigate and review how pharmacist education in Kerala aligns with UK pharmacist education; how the pharmacy model in Kerala compares to the UK model; and to consider novel ways of enabling faster / easier registration of Keralan pharmacists in the UK to ease the workforce pressures. My findings were shared with the workforce group following the trip.

Patient group directions (PGD) for Ulipristal Acetate and for Levonorgestrel, which support our local place based sexual health Emergency Hormonal Contraception (EHC) services, expired 30 September 2023: Each PGD along with supporting resources was reviewed and updated in time to ensure continuation of each locally commissioned service. Unfortunately, the East Riding council PGDs were delayed due to a flaw in their internal sign off process.

Humber North Yorkshire ICB invited me to join a dental PGD working group to develop and create a PGD for Fluoride paste. A viable PGD was produced which is now in use to support the delivery of a ICB wide dental caries prevention program.

Other activities during the year included preparation and delivery of face-to-face training events, webinars, videos and resources to support:

- Practice PTL meetings: MAS and PF
- Discharge Medicines Service
- Pharmacy services income event
- Pharmacy First Otoscope event
- Optical HCF events
- PharmOutcomes training to N Yorks and Humber LPC teams

Additional activities included a regular review of product files and data within PharmOutcomes platforms, preparation and sharing of service reports with commissioners; Monthly review of Optical referral service clinical data and activity; Responding to and resolving complaints and issues raised to the LPC; Representation of community pharmacy on the Humber Area Prescribing committee, Pharmacy Contraception Service steering group, Optical Hypertension steering group, Hull Drugs and Alcohol strategic partnership, Hull and East Riding Sexual Health network group, ICB PCN and practice pharmacist groups, Independent Prescriber Pathfinder clinical steering group, HNY Pharmacy First Steering group, North Lincolnshire PCN clinical directors group, Hull and ERY Contraception task and finish group, East Riding council pharmacies Process group, East Riding of Yorkshire council contract monitoring meetings, North Lincolnshire practice managers meetings; Continued interactions with pharma companies and their representatives.

## **Anthony Bryce: Health Integration & Public Health Lead**

### **Healthy Living Pharmacy (HLP)**

The Healthy Living Pharmacy (HLP) framework is aimed at achieving consistent provision of a broad range of health promotion interventions through community pharmacies to meet local need, improving the health and wellbeing of the local population and helping to reduce health inequalities.

All pharmacies across the Humber locality are now registered as a 'Healthy Living Pharmacy' (HLP) all of which collectively take part in public health initiatives, both locally and nationally in collaboration with local services. The adoption of HLPs marked a significant development for community pharmacy and its contribution to health promoting interventions.

Community pharmacies continue to provide valuable information and support to patients, clients, and customers in their efforts to remain both physically and mentally healthy as well as signposting individuals to local services, groups and the voluntary sector.

HLP wellbeing zones, and the information contained within them, are also used to maintain, and support, workforce wellbeing for community pharmacy staff. The HLP Facebook page continues to go from strength to strength with over 270 members. This communication medium is a valuable tool for pharmacy contractors to share good practice as well as being a vital resource for information and support around healthy living within the Humber locality.

HLP's are, and continue to be, a welcome and accessible location for clients, patients and customers to receive both flu and covid vaccinations as well as blood pressure readings via the Hypertension Case Finding Service.

### **Primary Care Networks (PCNs)**

Primary Care Networks (PCNs) are a key part of the NHS Long Term Plan, with general practices being a part of a network, typically covering 30,000-50,000 patients. The networks provide the structure and funding for services to be developed locally, in response to the needs of the patients they serve. It is fundamentally important, therefore, that community pharmacy teams are fully involved in the work of their PCN as PCNs will be critically important to the development of primary care services within our local area.

Community Pharmacy, via the implantation of PCN pharmacy leads in each PCN area, has continued to engage with PCNs (clinical directors, clinical pharmacists, PCN managers, practice managers) throughout 2023/2024. The number of PCNs has expanded during 2023/2024 increasing the number to twenty-three across the Humber locality and this is likely to expand further during 2024/2025.

The LPC continues to support PCN pharmacy leads across the Humber locality and has prepared several useful resources which contain information about the PCN as well as providing a dedicated PCN gaggle-group (email address) which is the communication method community pharmacies use to engage with one another and share good practice. Due to the continued workforce pressures that community pharmacies face, coupled with pharmacy closures across the Humber locality, it has been a challenging year for PCN pharmacy leads.



PCN pharmacy leads with the support of the LPC continue to look at ways of engaging with PCN's and the Integrated Care Board (ICB) and the various contacts throughout the Humber locality. It is our intention in 24/25 to look at ways in which we can further engage with PCNs with the potential introduction of 'place' based PCN Engagement Leads subject to the necessary funding.

### **Virtual Outcomes (VO) – Training Resources Online**

The LPC continued to commission the excellent online training platform, Virtual Outcomes, in order that contractors across the Humber could access a variety of training resources on a single, accessible platform <https://virtualoutcomes.co.uk/>. The training has proved to be popular amongst contractors and there has been an increased uptake of the number of pharmacies accessing many of the online training opportunities which has been supported by PCN pharmacy leads within their locality networks.

By the end of Q4 in 2023/24 Community Pharmacy Humber's contractor usage, **56.5%**, was well above the **44%** national average. On average 10-60 courses were accessed per month and had been viewed / completed by contractors which, though predominantly independent, also had substantial usage by CCA and AIMP contractors. In January 2024, a record number of courses were viewed (287) which were connected to the launch of Pharmacy First service.

Virtual Outcomes has continued to develop and provides additional courses such as the NHS Pharmacy Contraception service, Advanced Lateral Flow Device Test service, Pharmacy First, Flu Vaccination service, Atopic Eczema, Public Health campaigns, Bites and Stings, Smoking Cessation service (SCS), Hypertension Case Finding service and courses on the Pharmacy contract and HLP, all of which are being widely utilised by contractors throughout the Humber locality.

**Joanne Carter: Office Manager & Kate Stark: Administration Officer**

We know you have all faced some tough times over the past year as we all cope with team pressures, pharmacy closures, and the introduction of new services etc. We want to let you know that the LPC is always here for pharmacy teams to help you with anything you may need to know. That is why we have looked at our communications and thought about how best we can get information across to you.

We asked you in a survey, and had discussions with the LPC Committee, about how best to support pharmacy teams with our comms. Since then, we have updated the content on our website, bringing you a new page for Events & Training, Podcasts, and more... The Homepage has also been streamlined to bring you the latest news and quicker access to important service information such as Pharmacy First and Blood Pressure Checks. Why not take a look now! [www.communitypharmacyhumber.co.uk](http://www.communitypharmacyhumber.co.uk)

We communicate with our contractors via many communications methods, so that you can always reach the latest information whether that be via your NHS shared email, social media, and Gaggle mail. We have sent 55 Weekly Information Digests this year which have also been tweaked to improve the layout and added in QR codes, we hope your pharmacy teams found them useful and that they kept you informed of the latest updates as they happen.

The admin team have helped to organise several training sessions for you including Local Practical Vaccinations training, DMS training, Maximising Pharmacy Income training, Launch of SCS across Humber training, and Ear & Otoscope Training. We hope all that attended found these events useful. We hope to support you by offering more training events in the future.

Finally, if there is anything else you would like to see from us, training you would like to see offered or you have suggestions of alternative communication channels please do let us know. [Humber.lpc@nhs.net](mailto:Humber.lpc@nhs.net).

## Members' attendance at LPC meetings 2023-2024

Members of the committee are required to attend the LPC meeting regularly and provide input to those meetings. Members are also required to attend meetings on behalf of the LPC and pharmacy contractors. Expenses incurred by LPC members representing the LPC at meetings and events, including mileage claims. These include locum cover paid to contractors. The term of the previous committee was extended slightly, which made this year slightly shorter and ran from 1<sup>st</sup> July 2023 until 31<sup>st</sup> March 2024.

Members		Represents	Possible	Attended	Expenses
Annette Mauder		CCA	11*	9*	£0
Jon Whitelam	Treasurer	CCA	11*	11*	£2550
Tom Hajdas		AIMp	7	4	£1359.60
Jiun Chow		Independent	7	5	£1400
Abayomi Olusanya		Independent	11*	8*	£1360.32
Nick Hamilton		CCA	7	7	£1809.60
Taffazzal Hague		Independent	6	6	£1496.90
Andre Amaral		Independent	6	6	£1120
Owynn Baker		Independent	6	3	£128
<b>Appointed Officers</b>					
Paul McGorry		CEO	11*	11	N/A
Joanne Carter		Office Manager	11*	11	N/A
Caroline Hayward		PDP	7	2	N/A
Katie Stark		Admin Officer	7	2	N/A
Anthony Bryce		HIPHL	7	2	N/A
Joanne Lane		Employed Chair	11*	11*	N/A
<b>PSNC Representative</b>					
David Broome		PSNC	6	3	N/A

\*Includes LPC Executive Committee meetings

## LPC Account 2023/24

### Details of Meetings and Travel Expenses

Events – services support and training	£1685.38
Events – Venue & catering	£2071.21
LPC committee meeting expenses – venue & catering	£3413.02

## Treasurer's Report



*Operating under Nolan principles, the LPC considers that members carrying out duties on behalf of pharmacy contractors should not be out of pocket. The LPC operates within a robust accountability and governance framework which is regularly monitored.*

The LPC is funded by a contractor levy which was once again unchanged for the eighth consecutive year. The levy stands at £23,628 per month and is collected as a percentage of net ingredient cost from contractors by the NHS BSA. The levy also contributes to the activities of Community Pharmacy England (CPE); the LPC paid £69,815 in levies to CPE across 2023/24, an increase of £7,557 over the previous financial year. As with previous years the Levy was not the only source of income for the LPC, some of the funding grants from NHS England, NHSE&I and the Humber and North Yorkshire Partnership ICB (HNYP) continued into this financial year. We also continued to trade successfully with commissioners through the provision of PharmOutcomes (PO) licences, and platform development services, which totalled £122,030 and covered our purchase of PO licences for you, our contractors. Our gross income for the year was £515,426.

Costs were well controlled over the year. The total expenditure for the year of £406,933 resulted in an operating surplus of £88,203 at the end of the year. Having surrendered the lease on the LPC office and moved to a working from home model in May 23 rental costs were dramatically reduced this year. These will increase in the forthcoming year as we take up the lease on a new more cost-effective office. Payroll costs decreased by £21,769 due to retirement, and other changes, and remain under review. This year's payroll represented 33% of our income compared to 37% in 2022/2023.

Our bank balance of £476,108 is lower than our closing figure of £555,488 in 2022/2023. This is the result of a need to continue funding pilots from the LPC funding account, but with a noticeable decline in the securing of new grants during this financial year, and while some pilots have as yet unspent funds.

The LPC also decided across the year to absorb the over-delivery of some pilot services, such as WiCS, to the amount of £2262.

The balance of the grants which remain unspent are shown within the creditors falling due within one year section of the accounts and total £160,547. When this is subtracted from our bank balance it shows a true LPC balance of £337,345 which is higher than our closing balance in the previous year. The levy to CPE for 24/25 will increase to £82,888 pa, an increase of £13,073 (18.7%). Having moved to a three-year budgeting model the previous year, the LPC can still accommodate this increase without increasing the contractor levy.

During the course of the year, we reviewed our financial support arrangements and decided to change accountants from Smailes Goldie to Robson Jackson Licence to better suit the needs of the organisation and contractors.

Financial statements for the period are presented below for your information.

**Jonathan Whitelam: Treasure**

**UNAUDITED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2024**  
**FOR**  
**HUMBER LOCAL PHARMACEUTICAL COMMITTEE**



**HUMBER LOCAL PHARMACEUTICAL COMMITTEE**

**CONTENTS OF THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2024**

	<b>Page</b>
<b>Committee Information</b>	1
<b>Client Approval Certificate</b>	2
<b>Income Statement</b>	3
<b>Balance Sheet</b>	4
<b>Notes to the Financial Statements</b>	5
<b>Chartered Accountants' Report</b>	8
<b>Detailed Income and Expenditure Account</b>	9

**HUMBER LOCAL PHARMACEUTICAL COMMITTEE**

**COMPANY INFORMATION  
FOR THE YEAR ENDED 31 MARCH 2024**

**TRADING ADDRESS:**

PO Box 656  
Hull  
East Yorkshire  
HU9 9RL

**SECRETARY:**

P J McGorry

**CHAIRPERSON:**

J Lane (appointed 1 July 2023)  
P Robinson retired 30 June 2023)

**ACCOUNTANTS:**

Jackson Robson Licence Limited  
33-35 Exchange Street  
Driffield  
East Yorkshire  
YO25 6LL

**HUMBER LOCAL PHARMACEUTICAL COMMITTEE**

**CLIENT APPROVAL CERTIFICATE  
FOR THE YEAR ENDED 31 MARCH 2024**

In accordance with the terms of our engagement of Jackson Robson Licence Limited, I approve the financial statements for the year ended 31 March 2024 which comprise the Income and Expenditure Account, the Balance Sheet and the related notes. I acknowledge my responsibility for the financial statements and for providing Jackson Robson Licence Limited with all information and explanations necessary for their compilation.

**ON BEHALF OF THE COMMITTEE:**

P J McGorry  
Secretary

Date: 26 July 2024

## HUMBER LOCAL PHARMACEUTICAL COMMITTEE

### INCOME STATEMENT FOR THE YEAR ENDED 31 MARCH 2024

	Notes	2024 £	2023 £
<b>INCOME</b>		515,426	592,975
Cost of sales		<u>404,675</u>	<u>552,342</u>
<b>GROSS SURPLUS</b>		110,751	40,633
Administrative expenses		<u>26,935</u>	<u>36,941</u>
		83,816	3,692
Other operating income		<u>-</u>	<u>1,743</u>
<b>OPERATING SURPLUS</b>		83,816	5,435
Interest receivable and similar income		<u>4,387</u>	<u>318</u>
<b>SURPLUS BEFORE TAXATION</b>		88,203	5,753
Tax on surplus		<u>-</u>	<u>60</u>
<b>SURPLUS FOR THE FINANCIAL YEAR</b>		<u>88,203</u>	<u>5,693</u>

The notes form part of these financial statements

## HUMBER LOCAL PHARMACEUTICAL COMMITTEE

### BALANCE SHEET 31 MARCH 2024

	Notes	2024 £	£	2023 £	£
<b>FIXED ASSETS</b>					
Tangible assets	3		1,892		1,625
<b>CURRENT ASSETS</b>					
Debtors	4	19,892		2,202	
Cash at bank and in hand		<u>476,123</u>		<u>553,297</u>	
		496,000		555,499	
<b>CREDITORS</b>					
Amounts falling due within one year	5	<u>160,562</u>		<u>307,982</u>	
<b>NET CURRENT ASSETS</b>			<u>335,453</u>		<u>247,517</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			<u>337,345</u>		<u>249,142</u>
<b>GENERAL FUND</b>					
General fund			<u>337,345</u>		<u>249,142</u>
			<u>337,345</u>		<u>249,142</u>

The notes form part of these financial statements

## HUMBER LOCAL PHARMACEUTICAL COMMITTEE

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

#### 1. ACCOUNTING POLICIES

##### **Basis of preparing the financial statements**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

##### **Turnover**

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

##### *Rendering of services*

When the outcome of a transaction can be estimated reliably, turnover is recognised by reference to the stage of completion at the balance sheet date. Stage of completion is measured by reference to costs incurred at the balance sheet date.

Where the outcome cannot be measured reliably, turnover is recognised only to the extent of the expenses recognised that are recoverable.

##### **Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life. Plant and machinery etc - Straight line over 4 years

##### **Taxation**

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

##### **Deferred tax**

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

##### **Pension costs and other post-retirement benefits**

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

#### 2. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 6 (2023 - 8).

**HUMBER LOCAL PHARMACEUTICAL COMMITTEE**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 MARCH 2024**

**3. TANGIBLE FIXED ASSETS**

Plant and  
machinery  
etc  
£

**COST**

At 1 April 2023	2,364
Additions	<u>1,144</u>
At 31 March 2024	<u>3,508</u>

**DEPRECIATION**

At 1 April 2023	739
Charge for year	<u>877</u>
At 31 March 2024	<u>1,616</u>

**NET BOOK VALUE**

At 31 March 2024	<u>1,892</u>
At 31 March 2023	<u>1,625</u>

**4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2024	2023
	£	£
Trade debtors	16,516	509
Other debtors	<u>3,376</u>	<u>1,693</u>
	<u>19,892</u>	<u>2,202</u>

**5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2024	2023
	£	£
Trade creditors	2,891	43,586
Taxation and social security	4,242	6,375
Deferred income	145,792	251,502
Other creditors	<u>7,637</u>	<u>6,519</u>
	<u>160,562</u>	<u>307,982</u>

Deferred income at 31 March 2024 comprises unspent monies on the following projects:

CPCS Support Role Funding	(3,596)
CP PCN Lead Interface Role	31,588
COPD Case Finding	75,906
Hypertension ABPM Kits	-
Optical Integration of Hypertension	21,053
LPC Workforce Project Support Funding	13,835
Walk In CPCS Project	(2,263)
HCF Refer to GP	<u>9,269</u>
	<u>145,792</u>

**HUMBER LOCAL PHARMACEUTICAL COMMITTEE**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 MARCH 2024**

**6. OTHER FINANCIAL COMMITMENTS**

Within other creditors is an amount of £2,346 relating to pension contributions yet to be paid at the year end (2023 - £2,089).



**CHARTERED ACCOUNTANTS' REPORT  
ON THE UNAUDITED FINANCIAL STATEMENTS OF  
HUMBER LOCAL PHARMACEUTICAL COMMITTEE**

In accordance with our terms of engagement, we have prepared for your approval the financial statements of Humber Local Pharmaceutical Committee for the year ended 31 March 2024 which comprise the Income Statement, Balance Sheet and the related notes from the committee's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at <http://www.icaew.com/en/membership/regulations-standards-and-guidance>.

This report is made solely to you in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Humber Local Pharmaceutical Committee and state those matters that we have agreed to state to the director of Humber Local Pharmaceutical Committee in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Humber Local Pharmaceutical Committee for our work or for this report.

You have approved the financial statements for the year ended 31 March 2024 and have acknowledged responsibility for them, for the appropriateness of the financial reporting framework adopted and for providing all information and explanations necessary for their compilation.

We have not been instructed to carry out an audit or a review of the financial statements of Humber Local Pharmaceutical Committee. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Jackson Robson Licence Limited  
33-35 Exchange Street  
Drifffield  
East Yorkshire  
YO25 6LL

Date: 26 July 2024

This page does not form part of the statutory financial statements

**HUMBER LOCAL PHARMACEUTICAL COMMITTEE**

**DETAILED INCOME AND EXPENDITURE ACCOUNT  
FOR THE YEAR ENDED 31 MARCH 2024**

	2024		2023	
	£	£	£	£
<b>Income</b>				
Statutory levies received	283,536		283,536	
PharmOutcomes services	88,190		51,100	
Other services support	33,840		16,301	
Funding	106,510		236,755	
Events and training	1,000		1,083	
Sponsorship	<u>2,350</u>		<u>4,200</u>	
		515,426		592,975
 <b>Cost of sales</b>				
Levies paid to PSNC	69,815		62,258	
PharmOutcomes expenditure	46,096		24,052	
Events services support	2,172		1,316	
Events training	1,380		69,801	
PCN expenses	17,860		5,554	
Travel and meeting expenses - employees	4,910		3,905	
Service support - equipment	633		21,139	
Travel and meeting expenses - members	15,561		15,292	
Service fee	45,684		125,328	
Wages and salaries	174,624		196,393	
Employer National Insurance	12,065		13,175	
Employer pension contributions	<u>13,875</u>		<u>14,129</u>	
		<u>404,675</u>		<u>552,342</u>
 <b>GROSS SURPLUS</b>		110,751		40,633
 <b>Expenditure</b>				
Rent and service charges	717		6,000	
Insurance	2,924		2,508	
Light and heat	283		2,556	
Telephone	-		1,604	
Post and stationery	1,157		610	
Advertising	2,403		305	
Office equipment	182		37	
Computer and website costs	7,709		5,193	
Sundry expenses	7,328		6,013	
Accountancy and payroll	3,039		2,769	
Celebration event	-		8,577	
Gifts	<u>232</u>		<u>115</u>	
		<u>25,974</u>		<u>36,287</u>
 Carried forward		84,777		4,346

This page does not form part of the statutory financial statements

**HUMBER LOCAL PHARMACEUTICAL COMMITTEE**

**DETAILED INCOME AND EXPENDITURE ACCOUNT  
FOR THE YEAR ENDED 31 MARCH 2024**

	2024		2023	
	£	£	£	£
Brought forward		84,777		4,346
<b>Finance costs</b>				
Bank charges		<u>84</u>		<u>63</u>
		84,693		4,283
<b>Depreciation</b>				
Computer equipment		<u>877</u>		<u>591</u>
		83,816		3,692
<b>Other operating income</b>				
Sundry receipts		<u>-</u>		<u>1,743</u>
		83,816		5,435
<b>Finance income</b>				
Deposit account interest		<u>4,387</u>		<u>318</u>
<b>NET SURPLUS</b>		<u>88,203</u>		<u>5,753</u>

This page does not form part of the statutory financial statements